Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Notes Payables (2016 - 2025)

Northwest Biotherapeutics' Notes Payables history spans 16 years, with the latest figure at $9.5 million for Q4 2025.

  • Quarterly results put Notes Payables at $9.5 million for Q4 2025, down 33.26% from a year ago — trailing twelve months through Dec 2025 was $9.5 million (down 33.26% YoY), and the annual figure for FY2025 was $9.5 million, down 33.26%.
  • Notes Payables for Q4 2025 was $9.5 million at Northwest Biotherapeutics, down from $13.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $20.0 million in Q3 2022 to a low of $2.2 million in Q1 2021.
  • The 5-year median for Notes Payables is $9.7 million (2022), against an average of $10.7 million.
  • The sharpest move saw Notes Payables surged 5162.22% in 2021, then plummeted 74.39% in 2023.
  • Year by year, Notes Payables stood at $7.1 million in 2021, then skyrocketed by 116.82% to $15.4 million in 2022, then plummeted by 74.39% to $3.9 million in 2023, then skyrocketed by 259.69% to $14.2 million in 2024, then crashed by 33.26% to $9.5 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $9.5 million, $13.6 million, and $16.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.